BROMOCRIPTINE IN THE TREATMENT OF POST-POLIO FATIGUE
Authors:
- Jerald R. ZimmermanJZJerald R. Zimmerman
- Susan J. CreangeSCSusan J. Creange
- Todd LewisTLTodd Lewis
- Terry MolzenTMTerry Molzen
- Nancy M. FrickNFNancy M. Frick
- 1 September 1996
- journal article
- clinical trial
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 75 (5) , 340-347
Abstract
Fatigue is the most commonly reported and most disabling of all post-polio sequelae (PPS). Bromocriptine mesylate (Parlodel) was employed in a placebo-controlled trial in five survivors of paralytic polio who continued to report moderate to severe daily fatigue after complying with the conservative treatments prescribed for PPS. Placebo was given for 4 wk followed by increasing doses of bromocriptine mesylate, administered at 12:00 pm for 28 days, which reached a total dose of 12.5 mg/day. Three subjects reported marked symptom improvement on bromocriptine but not on placebo. Their reported difficulty with attention, concentration, word finding, mind wandering, memory, thinking clearly, and fatigue on awakening was significantly negatively correlated with days on bromocriptine but not with days on placebo. Before the drug trial began, responders had clinically impaired performance on neuropsychologic tests of attention and information processing speed, more than twice as many hyperintensities on magnetic resonance imaging of the brain, abnormally low fasting adrenocorticotropic hormone levels, and nearly double the mean plasma prolactin level compared with nonresponders. The implications of these findings for the pathophysiology of fatigue are discussed. A double-blind, placebo-controlled, multicenter study will be needed to confirm bromocriptine's efficacy in treating attentionally and neurophysiologically impaired polio survivors whose severe and disabling fatigue does not respond to conservative therapies.Keywords
This publication has 25 references indexed in Scilit:
- Polioencephalitis and the Brain Fatigue Generator Model of Post-Viral Fatigue SyndromesJournal of Chronic Fatigue Syndrome, 1996
- Post-polio sequelae and the paradigms of the 50s: Newtie, Ozzie, and Harriet versus Paradigms of Caring and a future for rehabilitation in AmericaArchives of Physical Medicine and Rehabilitation, 1995
- A Double‐Blind, Placebo‐Controlled Trial of High‐Dose Prednisone for the Treatment of Post‐Poliomyelitis SyndromeAnnals of the New York Academy of Sciences, 1995
- A Double‐Blind, Placebo‐Controlled, Trial of Amantadine for the Treatment, of Fatigue in Patients with the, Post‐Polio SyndromeAnnals of the New York Academy of Sciences, 1995
- Pathophysiology of a Central Cause, of Post‐Polio Fatigue aAnnals of the New York Academy of Sciences, 1995
- Antioxidant Properties of Bromocriptine, a Dopamine AgonistJournal of Neurochemistry, 1994
- The neuropsychology of post-polio fatigueArchives of Physical Medicine and Rehabilitation, 1993
- Effect of Age on D2 Dopamine Receptors in Normal Human Brain Measured by Positron Emission Tomography and 11C-RacloprideArchives of Neurology, 1993
- Dopamine Receptor Sensitivity Changes with Chronic StimulantsAnnals of the New York Academy of Sciences, 1988
- Effects of Age on Dopamine and Serotonin Receptors Measured by Positron Tomography in the Living Human BrainScience, 1984